80065406 - Treatment of Early-Stage Non-Small Cell Lung Cancer: Addressing Key Questions in an Evolving Treatment Landscape

Wednesday, July 31, 2024, 12:00 PM - Thursday, July 31, 2025, 12:00 PM, Online

Three self-study modules, two group tasks and two live sessions addressing the treatment of patients with early-stage non-small cell lung cancer.

Click on CME activity link: Treatment of Early-Stage Non-Small Cell Lung Cancer

 

1. Integrate clinical trial data and expert insights and guidance regarding adjuvant immunotherapy into treatment considerations in patients with early-stage NSCLC.
2. Integrate clinical trial data and expert insights and guidance regarding neoadjuvant immunotherapy into treatment considerations in patients with early-stage NSCLC.
3. Identify immune-related adverse events in patients with early-stage NSCLC being treated with adjuvant or neoadjuvant immunotherapy.
4. Implement strategies to mitigate or manage immune-related toxicities in patients with early-stage NSCLC being treated with adjuvant or neoadjuvant immunotherapy.

Mitigation of Relevant Financial Relationships

Johns Hopkins University adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.